Iceland vs Luxembourg: Access to anti-retroviral drugs, female
Iceland
86.0%
in 2024
Luxembourg
87.0%
in 2024
Iceland rank
47th
Luxembourg rank
45th
Access to anti-retroviral drugs, female over time
- Iceland
- Luxembourg
How they compare
Luxembourg currently reports 87.0% against 86.0% in Iceland, a difference of 1.0%.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Iceland ahead.
Iceland ranks 47th and Luxembourg ranks 45th of 141 countries.
Iceland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Iceland | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 63.4% | 43.3% | 20.1% | Iceland |
| 2010s | 84.0% | 64.1% | 19.9% | Iceland |
| 2020s | 83.6% | 80.2% | 3.4% | Iceland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Iceland or Luxembourg?
- Luxembourg, at 87.0% against 86.0% in Iceland as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Iceland and Luxembourg?
- 1.0%, with Luxembourg ahead.
- How many years of comparable data are there for Iceland and Luxembourg?
- 25 years are reported by both, from 2000 to 2024.
- How do Iceland and Luxembourg rank globally for access to anti-retroviral drugs, female?
- Iceland ranks 47th and Luxembourg ranks 45th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.